LEADER 05244nam 2200685Ia 450 001 9910876706903321 005 20200520144314.0 010 $a9786612278976 010 $a1-282-27897-5 010 $a3-527-61630-6 010 $a1-280-55845-8 010 $a9786610558452 010 $a3-527-60075-2 035 $a(CKB)1000000000019299 035 $a(EBL)481878 035 $a(OCoLC)55689483 035 $a(SSID)ssj0000305877 035 $a(PQKBManifestationID)11238487 035 $a(PQKBTitleCode)TC0000305877 035 $a(PQKBWorkID)10293260 035 $a(PQKB)11049975 035 $a(MiAaPQ)EBC481878 035 $a(MiAaPQ)EBC4957256 035 $a(Au-PeEL)EBL4957256 035 $a(CaONFJC)MIL55845 035 $a(OCoLC)748537783 035 $a(EXLCZ)991000000000019299 100 $a20011217d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aPharmacogenomics $ethe search for individualized therapies /$fedited by Julio Licinio and Ma-Li Wong 210 $aWeinheim ;$a[Chichester?] $cWiley-VCH$dc2002 215 $a1 online resource (601 p.) 300 $aDescription based upon print version of record. 311 $a3-527-30380-4 320 $aIncludes bibliographical references and index. 327 $aPharmacogenomics The Search for Individualized Therapies; Acknowledgements; Preface; Contents; List of Contributors; Color Plates; 1 Introduction to Pharmacogenomics: Promises, Opportunities, and Limitations; Abstract; 1.1 Pharmacogenetics - The Roots of Pharmacogenomis; 1.2 Pharmacogenomics - It is Not just Pharmacogenetics; 1.2.1 Genetic Drug Response Profiles; 1.2.2 The Effect of Drugs on Gene Expression; 1.2.3 Pharmacogenomics in Drug Discovery and Drug Development; 1.3 Pharmacogenomics - Hopfe or Hype?; 1.4 References; 2 The Human Genome; Abstract; 2.1 Introduction 327 $a2.2 Expressed Sequence Tags (ESTs) and Computational Biology: The Foundation of Modern Genomic Science2.3 Microbial Genomics; 2.3.1 Computational Analysis of Whole Genomes; 2.3.2 Comparative Genome Analysis; 2.4 Genomic Differences that Affect the Outcome of Host-Pathogen Interactions: A Template for the Future of Whole-Genome-Based Pharmacologic Science; 2.5 More Lessons from the Human Genome; 2.5.1 Protein-Coding Genes; 2.5.2 Repeat Elements; 2.5.3 Genome Duplication; 2.5.4 Analysis of the Proteome; 2.5.5 DNA Variation 327 $a2.6 Biological Complexity and the Role of Medicine in the Future of the Genome2.7 Conclusion; 2.8 References; 3 Turning SNPs into Useful Markers of Drug Response; Abstract; 3.1 Introduction; 3.2 Two Approaches for Employing SNPs in Pharmacogenomics; 3.2.1 Candidate Gene Studies; 3.2.2 Whole Genome Linkage Disequilibrium Mapping Studies; 3.2.3 Comparison of Candidate Gene and Whole Genome LD Mapping; 3.3 How Many SNPs are Needed and What Kind are Useful for Pharmacogenomic Studies; 3.3.1 Location; 3.3.2 Frequency; 3.3.3 Haplotype Analysis 327 $a3.3.4 Number of SNPs Required for Whole Genome LD Mapping Studies3.4 Study Designs for Pharmacogenomic Analysis; 3.4.1 Challenges Unique to Pharmacogenomics; 3.4.2 Clinical Trials, Case-Control and Cohort Studies; 3.5 Analytical Issues is Pharmacogenomic Studies; 3.5.1 Effect of LD on Sample Size; 3.5.2 Multiple Hypothesis Testing; 3.5.3 Gene-Drug Interaction; 3.6 Development of Pharmacogenomic Markers; 3.7 Conclusion; 3.8 References; 4 Association Studies in Pharmacogenomics; Abstract; 4.1 Introduction; 4.2 Variability and ADR in Drug Response: Contribution of Genetic Factors 327 $a4.3 Multiple Inherited Genetic Factors Influence the Outcome of Drug Treatments4.3.1 Background; 4.3.2 Liver Metabolism Enzymes; 4.3.3 Transporters; 4.3.4 Plasma Binding Proteins; 4.3.5 Drug Targets; 4.4 Association Studies in Pharmacogenomics; 4.4.1 The Principles of Association Studies; 4.4.2 Study Design; 4.4.3 Direct Approach: A Hypothesis-Driven Strategy; 4.4.4 Indirect Approach: A Hypothesis-Generating Strategy; 4.5 SNP Assembly into Maps; 4.6 Strategies for Pharmacogenomic Association Studies; 4.6.1 Candidate Genes; 4.6.2 Genome-Wide Scan 327 $a4.7 Expected Benefits of Pharmacogenomics in Drug R & D 330 $aThis is the very first comprehensive coverage of pharmacogenomics - a new discipline that will revolutionize health care.Pharmacogenomics leads to the understanding of the key genetic differences between individuals and will permit the individual tailoring of pharmacological treatments. Improved therapeutics can reach new levels by being able to differentiate between individuals according to their susceptibility to disease processes or adverse effects of medication. Pharmacogenomics also contributes to the discovery of new targets for drug development.Outstanding experts in the field p 606 $aPharmacogenomics 615 0$aPharmacogenomics. 676 $a615.1 676 $a615.19 676 $a615.7 701 $aLicinio$b J$0921196 701 $aWong$b Ma-Li$01752146 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910876706903321 996 $aPharmacogenomics$94187371 997 $aUNINA